Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II catumaxomab plus systemic chemotherapy for peritoneal carcinomatosis from gastric or colorectal adenocarcinoma
2010-022810-26Phase 2Completed
- Sponsor
- University of Witten/Herdecke
- Start
- Nov 2010
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in peritoneal carcinomatosis (PC), gastric adenocarcinoma and colorectal adenocarcinoma, sponsored by University of Witten/Herdecke. Primary endpoints: Incidence of clinically significant malignant ascites within 9 months and Symptom- and progression-free survival. Started Nov 2010; status: completed.
02
Drugs
catumaxomab
03
Conditions
peritoneal carcinomatosis (PC)gastric adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on 2010-022810-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022810-26.